The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
Open accessAbstract
BACKGROUND Advanced recurrent ovarian cancer (ROC) is the leading cause of gynecologic cancer-related death in developed countries and new treatments are needed. Previous studies of immune checkpoint blockade showed low objective response rates (ORR) in ROC with no identified predictive biomarker. PATIENTS AND METHODS This phase 2 study of pembrolizumab (NCT02674061) examined 2 patient cohorts with ROC: cohort A received 1-3 prior lines of treatment with a platinum-free (PFI) or treatment-free interval (TFI) between 3-12 months and cohort B received 4-6 prior lines with a PFI/TFI of ≥ 3 months. Pembrolizumab 200 mg was administered intravenously every 3 weeks until cancer progression, toxicity, or completion of 2 years. Primary endpoints were ORR by Response Evaluation Criteria in Solid Tumors version 1.1 per blinded independent central review by cohort and by PD-L1 expression measured as combined positive score (CPS). Secondary endpoints included duration of response (DOR), disease control rate (DCR), progression free survival (PFS), overall survival (OS), and safety. RESULTS Cohort A enrolled 285 patients; the first 100 served as the training set for PD-L1 biomarker analysis. Cohort B enrolled 91 patients. ORR was 7.4% for cohort A and 9.9% for cohort B. Median DOR was 8.2 months for cohort A and not reached for cohort B. DCR was 37.2% and 37.4%, respectively, in cohorts A and B. Based on the training set analysis, CPS 1 and 10 were selected for evaluation in the confirmation set. In the confirmation set, ORR was 4.1% for CPS<1, 5.7% CPS ≥1, and 10.0% for CPS ≥10. PFS was 2.1 months for both cohorts. Median OS was not reached for cohort A and was 17.6 months for cohort B. Toxicities were consistent with other single-agent pembrolizumab trials. CONCLUSIONS Single-agent pembrolizumab showed modest activity in patients with ROC. Higher PD-L1 expression was correlated with higher response. CLINICAL TRIAL NUMBER Clinicaltrials.gov, NCT02674061.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Rubin, M., & Stephen, C. D. (1993) · Cited by 3,149
PD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291 · cited 2×
“It is important to note that across studies of different checkpoint inhibitors, PD-L1 assays use different antibodies with a variety of cut points, each with unique and different thresholds for defining PD-L1 positivity [17, 18].”
BackgroundJayson, G. C., Kohn, E. C., Kitchener, H. C., & Ledermann, J. A. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62146-7 · Cited by 1,850
Self-citationHamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378
Matulonis, U. A., Sood, A. K., Fallowfield, L., Howitt, B. E., Sehouli, J., & Karlan, B. Y. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.61 · Cited by 1,362
Self-citationHirsch, F. R., McElhinny, A., Stanforth, D., Ranger-Moore, J., Jansson, M., Kulangara, K., Richardson, W., Towne, P., Hanks, D., Vennapusa, B., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.2228 · Cited by 1,270
Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., Kanai, M., Mori, Y., Matsumoto, S., Chikuma, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3397 · Cited by 1,180
Strickland, K. C., Howitt, B. E., Shukla, S. A., Rodig, S., Ritterhouse, L. L., Liu, J. F., Garber, J. E., Chowdhury, D., Wu, C. J., D’Andrea, A. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7277 · Cited by 620
Self-citationKulangara, K., Zhang, N., Corigliano, E., Guerrero, L., Waldroup, S., Jaiswal, D., MS, M. J., Shah, S., Hanks, D., Wang, J., et al. (2019) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0043-oa · Cited by 536
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
Tanyi, J. L., Bobisse, S., Ophir, E., Tuyaerts, S., Roberti, A., Genolet, R., Baumgartner, P., Stevenson, B. J., Iseli, C., Dangaj, D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao5931 · Cited by 450
The National Academies of Sciences, Engineering and Medicine
(2020) · The Grants Register 2021 · doi:10.1057/978-1-349-95988-4_100311 · Cited by 370
Müller, P., Kreuzaler, M., Khan, T., Thommen, D. S., Martin, K., Glatz, K., Savic, S., Harbeck, N., Nitz, U., Gluz, O., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac4925 · Cited by 349
Lee, J.-M., Cimino-Mathews, A., Peer, C. J., Zimmer, A., Lipkowitz, S., Annunziata, C. M., Cao, L., Harrell, M. I., Swisher, E. M., Houston, N., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1340 · Cited by 242
Characterization of hydrous species in minerals by high-speed proton MAS-NMR
Yesinowski, J. P., Eckert, H., & Rossman, G. R. (1988) · Journal of the American Chemical Society · doi:10.1021/ja00213a007 · Cited by 200
Epigenetics and immunotherapy: The current state of play
Dunn, J., & Rao, S. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.04.012 · Cited by 189
The role of immune checkpoint inhibition in the treatment of ovarian cancer
Gaillard, S. L., Secord, A. A., & Monk, B. J. (2016) · Gynecologic Oncology Research and Practice · doi:10.1186/s40661-016-0033-6 · Cited by 164
Disis, M. L., Patel, M. R., Pant, S., Hamilton, E. P., Lockhart, A. C., Kelly, K. L., Beck, J. T., Gordon, M. S., Weiss, G. J., Taylor, M. H., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.5533 · Cited by 143
Konstantinopoulos, P. A., Waggoner, S. E., Vidal, G. A., Mita, M. M., Fleming, G. F., Holloway, R. W., Le, L. V., Sachdev, J. C., Chapman‐Davis, E., Colón‐Otero, G., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.106 · Cited by 143
Self-citationHowitt, B. E., Strickland, K. C., Sholl, L. M., Rodig, S. J., Ritterhouse, L. L., Chowdhury, D., D’Andrea, A. D., Matulonis, U. A., & Konstantinopoulos, P. A. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1277308 · Cited by 116
Self-citation“Ovarian cancers: Evolving paradigms in research and care”
Alvarez, R. D., Karlan, B. Y., & Strauss, J. F. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.04.541 · Cited by 94
BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer
Wieser, V. E., Gaugg, I., Fleischer, M., Shivalingaiah, G., Wenzel, S., Sprung, S., Lax, S., Zeimet, A. G., Fiegl, H., & Marth, C. (2018) · Oncotarget · doi:10.18632/oncotarget.24770 · Cited by 92
Varga, A., Piha-Paul, S. A., Ott, P. A., Mehnert, J. M., Berton-Rigaud, D., Morosky, A., Zhao, G. Q., Rangwala, R. A., & Matei, D. E. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.5513 · Cited by 49
Bellone, S., Buza, N., Choi, J., Zammataro, L. A., Gay, L. M., Elvin, J. A., Rimm, D. L., Liu, Y., Ratner, E., Schwartz, P. E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1805 · Cited by 49
Self-citationMoving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer
Alvarez, R. D., Matulonis, U. A., Herzog, T. J., Coleman, R. L., Monk, B. J., & Markman, M. M. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.03.005 · Cited by 39
Self-citation
Cited by
Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
Martin, J. D., Cabral, H., Stylianopoulos, T., & Jain, R. K. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0308-z · Cited by 682
Konstantinopoulos, P. A., Waggoner, S., Vidal, G. A., Mita, M., Moroney, J. W., Holloway, R., Van Le, L., Sachdev, J. C., Chapman-Davis, E., Colon-Otero, G., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1048 · Cited by 563
Self-citationDisis, M. L., Taylor, M. H., Kelly, K., Beck, J. T., Gordon, M., Moore, K. M., Patel, M. R., Chaves, J., Park, H., Mita, A. C., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.6258 · Cited by 437
Pujade-Lauraine, E., Fujiwara, K., Ledermann, J. A., Oza, A. M., Kristeleit, R., Ray-Coquard, I.-L., Richardson, G. E., Sessa, C., Yonemori, K., Banerjee, S., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00216-3 · Cited by 416
Self-citationClinical and translational advances in ovarian cancer therapy
Konstantinopoulos, P. A., & Matulonis, U. A. (2023) · Nature Cancer · doi:10.1038/s43018-023-00617-9 · Cited by 394
Self-citation
Metadata
- Authors
- Matulonis, U. A., Shapira-Frommer, R., Santin, A. D., Lisyanskaya, A. S., Pignata, S., Vergote, I., Raspagliesi, F., Sonke, G. S., Birrer, M., Provencher, D. M., Sehouli, J., Colombo, N., González-Martín, A., Oaknin, A., Ottevanger, P. B., Rudaitis, V., Katchar, K., Wu, H., Keefe, S., Ruman, J., & Ledermann, J. A.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 30
- Issue
- 7
- Pages
- 1080-1087
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2890261294
- Cited by
- 845
- References
- 26
- FWCI
- 75.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.